SOURCE: Pacific Biomarkers

Pacific Biomarkers

January 27, 2016 13:11 ET

Pacific Biomarkers Announces the Appointment of Amar Sethi, MD, PhD, as Its President

SEATTLE, WA--(Marketwired - January 27, 2016) - Pacific Biomarkers today announced the appointment of Amar A. Sethi, MD, PhD as its new President. Dr. Sethi continues in his role as Chief Scientific Officer.

The President of Pacific Biomarkers is the senior business manager and business strategy director reporting directly to the company's CEO. The President will provide leadership to the company's Senior Operations Group, which is responsible for responding to the ever-changing business and operational needs of Pacific Biomarkers and service improvement to its clients. The President will drive strategic development plans that will keep PBI at the forefront of specialty laboratory services for pharmaceutical and diagnostic product development. In his continuing Chief Scientific Officer role, he will also be in charge of fostering growth of the company through scientific and technical innovation in the field of laboratory services for clinical development. 

Dr. Sethi is trained as a physician at the University of Copenhagen in Denmark (1996) and became board certified in chemical pathology by the National Board of Health, Denmark in 2005. In 2003 he was awarded a PhD in Genetic Epidemiology after discovering the genetic background of essential hypertension from the same institution . During 2005-2008 he was a postdoctoral fellow at the National Heart, Lung, and Blood Institute, Pulmonary and Vascular Medicine Branch, National Institutes of Health (NIH), and in 2008 he commenced a clinical chemistry fellowship in the Department of Laboratory Medicine, NIH overseeing the Immunology section while continuing his research. Dr. Sethi holds numerous awards and honors in both Denmark and the US, has presented extensively at international scientific meetings, and has published widely in international, peer-reviewed journals. 

"We are extremely pleased to promote a physician-scientist of Dr. Sethi's stature to President of Pacific Biomarkers," commented Ron Helm, the company's CEO. "Amar's arrival several years ago at PBI reinforced our standing and reputation in the industry as the premier provider of esoteric testing services to pharma and diagnostic companies in the areas of cardiovascular, metabolic, and bone and joint diseases. Amar's business experience coupled with his scientific experience will further enhance PBI's operation and reputation in our areas of expertise. His business acumen dovetails perfectly with our focus of positioning Pacific Biomarker's business for the future and continued growth."

About Pacific Biomarkers (PBI)
Established in 1989, PBI provides clinical biomarker laboratory services and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The Company provides expert services in the areas of cardiovascular and musculoskeletal diseases, diabetes, obesity, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, New York State, and the Lipid Standardization Program. PBI clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies. PBI also provides clinical biomarker services focusing on the emerging field of biomarker assay development and testing. Services include validating and performing custom assays for novel clinical biomarkers, immunogenicity testing, and multiplex testing. PBI is headquartered in Seattle, Washington.

For more information about PBI, visit the company's web site at

Contact Information

  • Pacific Biomarkers
    Ronald Helm
    Chief Executive Officer
    (206) 298-0068